Overview

• The multi-analyte assay analyzes chromosomal aneuploidy, tumor-specific mutations, and T and B cell receptor sequences from small cerebrospinal fluid samples.
• In a validation cohort, the combined markers delivered more than 80% sensitivity with 100% specificity, yielding no false positives among noncancer cases.
• Researchers evaluated 206 CSF specimens spanning high-grade gliomas, medulloblastomas, brain metastases, and central nervous system lymphomas.
• Immune repertoire profiling differentiated cancer from noncancer samples, providing biological context that may aid complex diagnostic scenarios.
• The findings were published Aug. 25 in Cancer Discovery with National Institutes of Health support, and broader prospective testing is needed before routine clinical use.